XL Therapeutics Ltd.

XL Therapeutics Ltd. is a pioneering biopharmaceutical company dedicated to developing innovative small molecule compounds (SMCs) aimed at treating patients suffering from Wiskott-Aldrich syndrome (WAS) and X-linked thrombocytopenia (XLT). These rare primary human immunodeficiencies stem from the absence or suboptimal function of the WAS protein (WASp). Located at 2 Ilan Ramon St., Ness Ziona, Israel 7403635, IL, XL Therapeutics is committed to advancing treatments that address the molecular defects affecting protein stability in WAS/XLT patients.

XL Therapeutics focuses on protecting WASp from degradation, with the goal of restoring normal or near-normal protein levels to improve immune cell function. The company has identified SMCs that bind to WASp, stabilizing the protein by preventing ubiquitylation and proteasomal degradation. These WASp-binding SMCs are undergoing rigorous development to produce a lead SMC with drug-like properties and a favorable safety profile. This approach holds the promise of a novel treatment for WAS/XLT patients, significantly impacting their quality of life.

XL Therapeutics Ltd. is dedicated to pushing the boundaries of biotechnology research to provide groundbreaking therapeutic solutions. The company's commitment to innovation and patient well-being positions it as a key player in the biopharmaceutical sector. We invite the management of XL Therapeutics Ltd. to enhance your company’s visibility further by creating a customized and exclusive company showcase and product listing on our platform.